Cargando…

Wogonin reverses the drug resistance of chronic myelogenous leukemia cells to imatinib through CXCL12-CXCR4/7 axis in bone marrow microenvironment

BACKGROUND: In the current study, chronic myeloid leukemia (CML) cells (K562 and KU812) co-cultured with human bone marrow stromal cells (BMSCs) were significantly less sensitive to imatinib (IM). The activation of the CXCL12-CXCR4/7 axis plays an important role in the protective effect of the bone...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cao, Hanbo, Gao, Yuan, Wang, Ruixuan, Guo, Qinglong, Hui, Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7575956/ https://www.ncbi.nlm.nih.gov/pubmed/33145265 http://dx.doi.org/10.21037/atm-20-1166

Ejemplares similares

Oroxyloside A Overcomes Bone Marrow Microenvironment-Mediated Chronic Myelogenous Leukemia Resistance to Imatinib via Suppressing Hedgehog Pathway
por: Zhang, Xiaobo, et al.
Publicado: (2017)

Oroxylin a Inhibits the Protection of Bone Marrow Microenvironment on CML Cells Through CXCL12/CXCR4/P-gp Signaling Pathway
por: Cao, Hanbo, et al.
Publicado: (2019)

Corrigendum: Oroxylin a Inhibits the Protection of Bone Marrow Microenvironment on CML Cells Through CXCL12/CXCR4/P-gp Signaling Pathway
por: Cao, Hanbo, et al.
Publicado: (2019)

Wogonin reversed resistant human myelogenous leukemia cells via inhibiting Nrf2 signaling by Stat3/NF-κB inactivation
por: Xu, Xuefen, et al.
Publicado: (2017)

Author Correction: Wogonin reversed resistant human myelogenous leukemia cells via inhibiting Nrf2 signaling by Stat3/ NF-κB inactivation
por: Xu, Xuefen, et al.
Publicado: (2021)

Retraction Note: Wogonin reversed resistant human myelogenous leukemia cells via inhibiting Nrf2 signaling by Stat3/NF-κB inactivation
por: Xu, Xuefen, et al.
Publicado: (2022)

Roles of the CXCL8-CXCR1/2 Axis in the Tumor Microenvironment and Immunotherapy
por: Han, Zhi-Jian, et al.
Publicado: (2021)

Ketoconazole Reverses Imatinib Resistance in Human Chronic Myelogenous Leukemia K562 Cells
por: Prado-Carrillo, Omar, et al.
Publicado: (2022)

BM microenvironmental protection of CML cells from imatinib through Stat5/NF-κB signaling and reversal by Wogonin
por: Xu, Xuefen, et al.
Publicado: (2016)

Wogonin induces cell cycle arrest and erythroid differentiation in imatinib-resistant K562 cells and primary CML cells
por: Yang, Hao, et al.
Publicado: (2014)

The treatment of pediatric chronic myelogenous leukemia in the imatinib era
por: Lee, Jae Wook, et al.
Publicado: (2011)

CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment
por: Giallongo, Cesarina, et al.
Publicado: (2022)

Regulative role of the CXCL13-CXCR5 axis in the tumor microenvironment
por: Tan, Ping, et al.
Publicado: (2018)

Correction: Wogonin induces cell cycle arrest and erythroid differentiation in imatinib-resistant K562 cells and primary CML cells
por: Yang, Hao, et al.
Publicado: (2020)

Imatinib Therapy in Chronic Myelogenous Leukemia and Thyroid Function Tests
por: Mashhadi, Mohammad Ali, et al.
Publicado: (2014)

CXCR4/CXCR7/CXCL12-Axis in Follicular Thyroid Carcinoma
por: Werner, Thomas Artur, et al.
Publicado: (2018)

The Role of the CXCL12/CXCR4/CXCR7 Chemokine Axis in Cancer
por: Shi, Yi, et al.
Publicado: (2020)

Targeting the CXCL12/CXCR4 axis in acute myeloid leukemia: from bench to bedside
por: Cho, Byung-Sik, et al.
Publicado: (2017)

Clinicopathologic significance of the CXCL1-CXCR2 axis in the tumor microenvironment of gastric carcinoma
por: Kasashima, Hiroaki, et al.
Publicado: (2017)

Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia
por: Shea, Lauren K., et al.
Publicado: (2017)

CXCL12-CXCR4 axis in feline mammary carcinoma
por: Ferreira, Fernando
Publicado: (2017)

Significance of CXCL12/CXCR4 Ligand/Receptor Axis in Various Aspects of Acute Myeloid Leukemia
por: Yazdani, Zinat, et al.
Publicado: (2020)

Translocation of heme oxygenase-1 contributes to imatinib resistance in chronic myelogenous leukemia
por: Schaefer, Bianca, et al.
Publicado: (2017)

Homoharringtonine enhances the effect of imatinib on chronic myelogenous leukemia cells by downregulating ZFX
por: Wu, Jingjing, et al.
Publicado: (2019)

CXCL5/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target
por: Zhang, Wen, et al.
Publicado: (2020)

Involvement of the CXCR7/CXCR4/CXCL12 Axis in the Malignant Progression of Human Neuroblastoma
por: Liberman, Julie, et al.
Publicado: (2012)

CXCL12/CXCR4/CXCR7 axis in placenta tissues of patients with placenta previa
por: Wu, Xia, et al.
Publicado: (2023)

CXCL12-CXCR4/CXCR7 Axis in Cancer: from Mechanisms to Clinical Applications
por: Yang, Yaru, et al.
Publicado: (2023)

CXCR4/CXCL12 Activities in the Tumor Microenvironment and Implications for Tumor Immunotherapy
por: Mezzapelle, Rosanna, et al.
Publicado: (2022)

Chaetocin antileukemia activity against chronic myelogenous leukemia cells is potentiated by bone marrow stromal factors and overcomes innate imatinib resistance
por: Truitt, L, et al.
Publicado: (2014)

Efficacy of imatinib mesylate-based front-line therapy in pediatric chronic myelogenous leukemia
por: Oh, Hyun Jin, et al.
Publicado: (2013)

Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells
por: Peng, Xing-Xiang, et al.
Publicado: (2012)

Mesenchymal soluble factors confer imatinib drug resistance in chronic myelogenous leukemia cells
por: Regev, Ofer, et al.
Publicado: (2020)

CXCR4/CXCL12/CXCR7 axis is functional in neuroendocrine tumors and signals on mTOR
por: Circelli, Luisa, et al.
Publicado: (2016)

CXCR4/CXCR7/CXCL12 axis promotes an invasive phenotype in medullary thyroid carcinoma
por: Werner, Thomas A, et al.
Publicado: (2017)

Role and implications of the CXCL12/CXCR4/CXCR7 axis in atherosclerosis: still a debate
por: Murad, Hussam A. S., et al.
Publicado: (2021)

Inhibition of the CXCL12/CXCR4-Axis as Preventive Therapy for Radiation-Induced Pulmonary Fibrosis
por: Shu, Hui-Kuo G., et al.
Publicado: (2013)

The CXCL12/CXCR4 chemokine ligand/receptor axis in cardiovascular disease
por: Döring, Yvonne, et al.
Publicado: (2014)

Emerging targets in cancer management: role of the CXCL12/CXCR4 axis
por: Cojoc, Monica, et al.
Publicado: (2013)

The Role of the CXCL12/CXCR4/ACKR3 Axis in Autoimmune Diseases
por: García-Cuesta, Eva M., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_795hqe0nnpnophfdtlsi5stp5m